{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:01Z","timestamp":1787721661247,"version":"build-2784847793"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, characterized by aggressive biological behavior and a high propensity for extrahepatic spread. The most common sites of metastasis are the lungs, regional lymph nodes, bones, adrenal glands, and peritoneum. In contrast, the paranasal sinuses are an unusual site for metastatic HCC, and involvement of the sphenoid sinus represents an even rarer event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>We report the case of a 67-year-old male patient who presented with transient diplopia, left eyelid ptosis, and refractory epistaxis as the initial clinical manifestations of a previously undetected HCC. Histopathological evaluation of the sinus mass and subsequent imaging confirmed a metastatic lesion from a silent primary liver tumor. The patient was managed using a multidisciplinary approach, undergoing radiation therapy to the sphenoid sinus for pain control and endovascular embolization of the sphenopalatine arteries for refractory epistaxis. In March 2026, a contrast-enhanced computed tomography (CT) scan revealed new osteolytic lesions, consistent with bone metastases, involving the proximal third of the left clavicle and the T9 vertebral body. The patient subsequently received further palliative radiotherapy to the left clavicle and T7-T9, and initiated first-line systemic therapy with atezolizumab plus bevacizumab, completing four cycles. Due to disease progression at multiple skeletal sites and in the sphenoid region, as revealed by a CT scan in June 2026, second-line treatment with lenvatinib was initiated and is ongoing at the latest follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite its rarity, the differential diagnosis of a paranasal sinus lesion should include the possibility of metastasis from HCC, particularly in patients with underlying chronic liver disease. Histopathological confirmation and a multidisciplinary approach are critical for optimizing therapeutic planning in this challenging clinical scenario.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1907582","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:51:14Z","timestamp":1787719874000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The unusual first sign of presentation of hepatocellular carcinoma: a rare case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Rocco","family":"Morra","sequence":"first","affiliation":[{"name":"Clinical Experimental Abdominal Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nappi","sequence":"additional","affiliation":[{"name":"Clinical Experimental Abdominal Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Zanaletti","sequence":"additional","affiliation":[{"name":"Clinical Experimental Abdominal Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Piccirillo","sequence":"additional","affiliation":[{"name":"Division of Hepatobiliary Surgery, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tarotto","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Stilo","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiore","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Izzo","sequence":"additional","affiliation":[{"name":"Division of Hepatobiliary Surgery, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Avallone","sequence":"additional","affiliation":[{"name":"Clinical Experimental Abdominal Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101571","DOI":"10.1016\/j.jhepr.2025.101571","article-title":"Hepatocellular carcinoma: Epidemiology, diagnosis and treatment","author":"Mauro","year":"2025","journal-title":"Jhep Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13070207","article-title":"Hepatocellular carcinoma: a comprehensive review","volume":"13","author":"Amin","year":"2025","journal-title":"Diseases"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2025.102403","article-title":"Signalling pathways in hepatocellular carcinoma (HCC) metastasis and invasion: Molecular mechanisms and therapeutic implications","volume":"45","author":"Das","year":"2026","journal-title":"Biochem Biophys Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.25259\/sni_77_2023","article-title":"Solitary metastasis to the skull as the first sign of hepatocellular carcinoma in a patient in long-term remission","volume":"14","author":"Bernstein","year":"2023","journal-title":"Surg Neurol Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"19458924261457745","DOI":"10.1177\/19458924261457745","article-title":"Cancer metastasis to the sinonasal cavity: Clinical characteristics and survival analysis in 35 patients","author":"Park","year":"2026","journal-title":"Am J Rhinol Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1323157","article-title":"Paranasal sinus involvement in metastatic carcinoma","volume":"73","author":"Abi-Fadel","year":"2012","journal-title":"J Neurol Surg Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24502","article-title":"Metastases to nasal cavity and paranasal sinuses","volume":"38","author":"L\u00f3pez","year":"2016","journal-title":"Head Neck"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2006.08.012","article-title":"Sinonasal metastatic hepatocellular carcinoma","volume":"28","author":"Huang","year":"2007","journal-title":"Am J Otolaryngol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.35420\/jcohns.2022.33.3.139","article-title":"A case of metastatic hepatocellular carcinoma in sphenoid sinus with intractable nasal bleeding controlled by radiation therapy","volume":"33","author":"Yi","year":"2022","journal-title":"J Clin Otolaryngol Head And Neck Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-022-02986-x","article-title":"A practical overview of CT and MRI features of developmental, inflammatory, and neoplastic lesions of the sphenoid body and clivus","volume":"64","author":"Nardi","year":"2022","journal-title":"Neuroradiology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1259\/bjrcr.20160111","article-title":"MR imaging findings of metastatic hepatocellular carcinoma in the nasal cavity: a rare site of spread","volume":"3","author":"Kang","year":"2016","journal-title":"Bjr Case Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s361045","article-title":"Skull base metastasis from hepatocellular carcinoma: clinical presentation and efficacy of radiotherapy","author":"Kim","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040539","article-title":"Metastatic tumors of the sinonasal cavity: a 15-year review of 17 cases","volume":"8","author":"Chang","year":"2019","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1907582\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:51:23Z","timestamp":1787719883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1907582\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":18,"alternative-id":["10.3389\/fonc.2026.1907582"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1907582","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1907582"}}